AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05888064 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: diffusion MRI sequences
Description: Diffusion MRI sequences will be optimized to derive more accurate estimates of microstructure and microvasculature of tumour and healthy organs: multiple b-values will be acquired and advanced diffusivity models considered. MRI sequences to derive tumour hypoxia (i.e. indicative of radioresistance) will be also considered along with MR spectroscopy to evaluate tumour microenvironment.
Study NCT04932772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: Technique: Include Rectus Abdominas Muscles (RAM), Oblique Abdominal Muscles (OAM). Tape will be applied on RAM using muscles technique from origin to insertion of muscle with a tension between15-35%. Band will be start on symphysis pubis with no tension and then women make stretch on the abdominal region by deep abdominal inspiration and will end at xyphoid process. Finally will perform on the right and left external oblique muscles the procedure will be start with no tension from bottom and of 6-12 ribs and then the hip will be place in flexion and rotation to opposite direction and the band will tape on pubic bone with tension between 15-35% (Kase et al., 2003).
Study NCT04932772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal Exercises
Description: Women in group B will receive abdominal muscles exercise (2 sessions/ week) for eight weeks. This program will be applied in both group A and B. The women will repeat the same exercise program on other days as home routine. This program is proposed by Kamel and Yousif, 2017, as based on the literature (Kamel and Yousif, 2017), there is no golden standard exercise program for DRAM. Illustrations of the exercises will be provided, so that the women could repeat the same exercise program on other days as a home routine. All the exercises will be performed while the subject tied a scarf around her abdomen. The following proposed one included sit ups, reverse sit-ups, reverse trunk twists, and U-seat exercises (Fig. 5). Each exercise was repeated 20 times and was increased by four repetitions each week throughout the interventions. In addition, a respiratory rehabilitation maneuver to involve the abdominal muscles, especially the transverse abdominis will be performed.
Study NCT04932772 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal Exercises
Description: Women in group B will receive abdominal muscles exercise (2 sessions/ week) for eight weeks. This program will be applied in both group A and B. The women will repeat the same exercise program on other days as home routine. This program is proposed by Kamel and Yousif, 2017, as based on the literature (Kamel and Yousif, 2017), there is no golden standard exercise program for DRAM. Illustrations of the exercises will be provided, so that the women could repeat the same exercise program on other days as a home routine. All the exercises will be performed while the subject tied a scarf around her abdomen. The following proposed one included sit ups, reverse sit-ups, reverse trunk twists, and U-seat exercises (Fig. 5). Each exercise was repeated 20 times and was increased by four repetitions each week throughout the interventions. In addition, a respiratory rehabilitation maneuver to involve the abdominal muscles, especially the transverse abdominis will be performed.
Study NCT05880524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dornase Alfa
Description: Patients will receive an intravenous dose of Dornase alfa twice within within 24±6 hours after symptom onset, administered as a bolus.
Study NCT05880524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Saline Solution
Description: Patients will receive an intravenous dose of Isotonic saline solution twice within within 24±6 hours after symptom onset, administered as a bolus.
Study NCT00916916 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: A blood draw will occur to take 10cc of blood to measure lanreotide levels.
Study NCT05640427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Groups D1 received general anesthesia with intravenous pump of 0. 2μg/kg/h dexmedetomidine to 30min before the end of the operation.Groups D2 received general anesthesia with intravenous pump of 0. 5μg/kg/h dexmedetomidine to 30min before the end of the operation.
Study NCT05640427 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: The same capacity of 0.9% normal saline was used in group C
Study NCT05280054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-101
Description: 360 mg capsules
Study NCT05280054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: 1000 mg oral
Study NCT04088942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity smoking cessation intervention
Description: 1. Varenicline for 12 weeks - Day 1-3: 0.5 mg daily. Dag 4-7: 0.5 mg two times daily. Thereafter 1 mg 2 times daily.~2. Group-sessions in 6 months:~Preparation phase: 5 sessions Day 1-14: 5 sessions Day 15-30: 5 sessions Day 31-60: 5 sessions Day 61-90: 5 sessions Day 90-180: 5 sessions c) Hotline and scheduled phone consultations:~1. A hotline is established which the high-intensity group can call.~2. Weekly calls to all patients in the project for 26 weeks. Call for 5-10 min. If the patient has not had relapse, there will be called week 34 and week 42. If the patient has had relapse, calls continue until relapse-free for 10 weeks, then week 34 and week 42.~   d) Buddy-arrangement: i. Patients who have completed the program and have become smoke-free, are matched with new ones in the program. A meeting frequency of approx. every 7-14 days. The first patients are matched with patients from pulmonary medical outpatient clinic who have ceased smoking.
Study NCT04088942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity smoking cessation intervention
Description: Varenicline prescribed for 12 weeks - Day 1-3: 0.5 mg daily. Dag 4-7: 0.5 mg two times daily. Thereafter 1 mg 2 times daily.
Study NCT06493084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAE102 injection
Description: intravenous drip or subcutaneous injection
Study NCT06493084 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: intravenous drip or subcutaneous injection
Study NCT06493084 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: intravenous drip or subcutaneous injection
Study NCT06306014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXL01
Description: Following a at least 10-days vancomycin treatment :~Oral EXL01 including:~* 10 capsules per day in week 1 and 2~* 4 capsules per day, in weeks 3 and 4~* 1 capsule per day in weeks 5 to 8 Phase I : EXL01 during a 8 weeks open-label period
Study NCT06306014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXL01
Description: Following a at least 10-days vancomycin treatment :~Oral EXL01 including:~* 10 capsules per day in week 1 and 2~* 4 capsules per day, in weeks 3 and 4~* 1 capsule per day in weeks 5 to 8 Phase II: EXL01 during a 8 weeks double blind placebo-controlled period
Study NCT06306014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Following a at least 10-days vancomycin treatment:~Oral placebo including:~* 10 capsules per day in week 1 and 2~* 4 capsules per day, in weeks 3 and 4~* 1 capsule per day in weeks 5 to 8 Phase II : Placebo during a 8 weeks double blind placebo-controlled period
Study NCT06560684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral F/TDF Pills
Description: For 8 weeks of each study period, the participant will take the study product at least weekly prior to anticipated RAI.
Study NCT06560684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TFV rectal douche
Description: For 8 weeks of each study period, the participant will take the study product at least weekly prior to anticipated rectal anal intercourse (RAI).
Study NCT04610970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3525 tablets
Description: TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
Study NCT06554067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation
Description: Ten minutes of active transcranial direct current stimulation
Study NCT06554067 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active transcranial direct current stimulation
Description: Ten minutes of active transcranial direct current stimulation
Study NCT06554067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active vagus nerve stimulation
Description: Ten minutes of active vagus nerve stimulation
Study NCT06554067 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active vagus nerve stimulation
Description: Ten minutes of active vagus nerve stimulation
Study NCT06554067 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: Ten minutes of sham tDCS
Study NCT06554067 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: Ten minutes of sham tDCS
Study NCT06554067 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham vagus nerve stimulation
Description: Ten minutes of sham VNS
Study NCT06554067 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham vagus nerve stimulation
Description: Ten minutes of sham VNS
Study NCT05724030 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: integrated pulmonary index
Description: integarted pumobary index monitoring
Study NCT05724030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: integrated pulmonary index
Description: integarted pumobary index monitoring
Study NCT05724030 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: saturation
Description: saturation monitorization
Study NCT05724030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: saturation
Description: saturation monitorization
Study NCT04830254 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation(TENS) device
Description: The Patients in group (A) received low-frequency TENS (frequency 4 Hz, pulse duration 200 μs,burst mode) was be applied through 2 output channels surface electrodes with an E2 TENS device, for 45 min per session, supramaximal stimulation to sympathetic ganglions in T12, L1, and L2, which innervate the lower extremity . For 45 min per session, three times per week, and for 12 weeks.
Study NCT04830254 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation(TENS) device
Description: The Patients in group (A) received low-frequency TENS (frequency 4 Hz, pulse duration 200 μs,burst mode) was be applied through 2 output channels surface electrodes with an E2 TENS device, for 45 min per session, supramaximal stimulation to sympathetic ganglions in T12, L1, and L2, which innervate the lower extremity . For 45 min per session, three times per week, and for 12 weeks.
Study NCT06189742 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Tezepelumab is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP).
Study NCT04735939 — intervention group
Intervention type: RADIATION
Intervention: radiotherapy
Description: Determine whether there is a difference in outcomes seen when patients are assigned to take their radiotherapy at either a morning time or evening time.
Study NCT05249179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pacifier
Description: Preterm infants in Groups 2 and 3 will suck a pacifier 3 times a day (09:00, 12:00, 15:00) for 3 minutes before feeding and then they will be fed with the O/G feeding tube.
Study NCT05249179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral stimulation
Description: Infants in groups 1 and 3 will receive a prefeeding oral stimulation program once a day, 15 to 30 minutes before a tube feeding. Oral stimulation programs will be delivered by trained nurses or pediatric physical therapies. Nurses will be trained to deliver the stimulation program to the infants, by a member from the pediatric physical therapies medical staff, before the beginning of the study. Based on Backman's principles, the pre-feeding oral stimulation program consisted of a 12-minute stimulation program that included stroking the cheeks, lips, gums, and tongue.
Study NCT06466356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducational Course for Suicide Prevention
Description: Baseline variables includes diagnosis using ICD-10 criteria for research and demographic variables such as age, sex, level of education and occupation. Following assessments will be used when including patients for the project: The General self-efficacy scale (GSE) with additional questions related to the theme of the psychoeducational topics, The mental pain questionnaire (MPQ, Alcohol Use Disorders Identification Test (AUDIT), Drug Use Disorders Identification Test (DUDIT) The Patient Health Questionnaire (PHQ-9), GAD-7, The SCS-Checklist and SCI-5. GSE, MPQ and PHQ-9 will be measured after intervention and after 6, 12, 24 and 60 months.
Study NCT06466356 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individual therapy session
Description: Baseline variables includes diagnosis using ICD-10 criteria for research and demographic variables such as age, sex, level of education and occupation. Following assessments will be used when including patients for the project: The General self-efficacy scale (GSE) with additional questions related to the theme of the psychoeducational topics, The mental pain questionnaire (MPQ, Alcohol Use Disorders Identification Test (AUDIT), Drug Use Disorders Identification Test (DUDIT) The Patient Health Questionnaire (PHQ-9), GAD-7, The SCS-Checklist and SCI-5. GSE, MPQ and PHQ-9 will be measured after intervention and after 6, 12, 24 and 60 months.
Study NCT06466356 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual (TAU) may include the use of psychotropic drugs, in and out-patient treatment, occupational therapy and other interventions the patients physician deem necessary.
Study NCT06466356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Treatment as usual (TAU) may include the use of psychotropic drugs, in and out-patient treatment, occupational therapy and other interventions the patients physician deem necessary.
Study NCT04899492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: 1 to 3 Motivational Interviewing (MI) should be performed after randomization by a psychotherapist
Study NCT04899492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Description: 6 Cognitive Behavioural Therapy (CBT) sessions should be performed after motivational interviewing up to 6 months by a psychotherapist
Study NCT04899492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Description: About 3 Hypnotherapy sessions should be performed after motivational interviewing up to 6 months by a hypnotherapist
Study NCT04899492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT)
Description: All patients will receive Nicotine Replacement Therapy (NRT) from randomization up to 6 months
Study NCT04899492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Description: All patients will receive Nicotine Replacement Therapy (NRT) from randomization up to 6 months
Study NCT04816890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M1 Pram P037
Description: Subcutaneous administration of M1 Pram P037 in combination with a basal insulin.
Study NCT04816890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin lispro
Description: Subcutaneous administration of insulin lispro in combination with a basal insulin.
Study NCT04201028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Conferencing Health Coaching with devices
Description: Devices
Study NCT04201028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Conferencing Health Coaching with no devices
Description: No Devices
Study NCT04554147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAITH! App-enhanced Hypertension Intervention
Description: FAITH! HTN App: The program promotes HTN self-management through a 10-week education module series on HTN. Participants will follow each module weekly and use a wireless home BP monitor for self-tracking which syncs to the app. The app includes module quizzes, a BP tracking dashboard and a moderated sharing board to foster discussion on HTN management.~Patient-Provider-CHW ICM. The patient-provider-CHW triad works together for personalized, collaborative goal setting. The patient will complete app modules, self-monitor BP, and engage with a sharing board integrating HTN topics. At weekly virtual visits (telephone or video), the CHW will record patient BPs, assist with addressing social determinants of health (SDOH) identified by the patient (eg, local community resources), and review HTN modules. The CHW will upload clinical/SDOH data to the patient electronic medical record (EMR) for FQHC care providers to review. This cycle will be completed weekly over the 10-week intervention.
Study NCT06437184 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ODP
Description: se previously
Study NCT06541119 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selective Peroneus longus excercise
Description: Weight bearing peroneus longus exercise
Study NCT05356624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Mobilization
Description: It is technique in which passive mobilization is applied by therapist to improve the normal position and by holding the passive glide active movement in restricted direction of motion to reduce pain or improve range of motion or function. A total of 3 sets of 10 repetition three times a week on alternate days for 6 week
Study NCT05356624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soft Tissue Mobilization
Description: in this technique for joint the passive glides are applied, for CMC joint mobilization patient hand is rest on table. The therapist grasp trapezium with one hand and 1st metacarpal between index and thumb of other hand to apply glide. A total of 3 sets of 10 repetition three times a week on alternate days for 6 weeks.
Study NCT05655390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Intervention Planning
Description: The therapy is based on the iFightDepression platform implemented by the European Alliance against Depression. The aim of this specific therapy is to help individuals to acquire strategies to regulate emotions and learn to tolerate discomfort preventing the imminent risk for suicidal behavior. The safety planning intervention will be conducted by identifying warning signs and provide each individual with personal and individualized coping strategies and sources of support. Main skills to be acquired and integrated for the individual are as it follows: 1) Contingency plan by five steps (identification of warning signs; applying internal coping strategies; network as distraction; safe environment; reasons for living and contact professionals), 2) Mindfulness, 3) Discomfort tolerance, and 4) Regulating emotions.
Study NCT05668429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrexafungerp
Description: carbon-14 (\[14\^C\])-Ibrexafungerp
Study NCT04751630 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise
Description: Online and structured exercise therapeutic program based on flexibility, strength, balance and aerobic exercises. The program have been supervised by an expert on the field and it participants will perform it under the supervision of an expert physiotherapist.
Study NCT06590376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: midwifery care based on swanson care theory
Description: All stages in the Midwifery Care and Counselling Practitioner Guide for Couples Experiencing Pregnancy Loss, which was developed by the researcher and included care, education and midwife counselling consisting of eight interviews, four of which were face-to-face and four by telephone, were applied.
Study NCT06669663 — intervention group
Intervention type: DRUG
Intervention: Pimonidazole hydrochloride (Hypoxyprobe™-1)
Description: Participants will receive Pimonidazole (non-CTIMP) prior to their surgery for OG cancer and then undergo intra-operative sampling.
Study NCT05962996 — intervention group
Intervention type: DEVICE
Intervention: Pupillometry
Description: Measurement of pain levels by pupillometry during the insertion of a deep venous catheter
Study NCT05158309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 8% Capsaicin patch
Description: Cutaneous pain was induced using a (5x10 cm) 8% topical capsaicin patch (transdermal patch, 'Qutenza', Astellas) on the volar part of the dominant right forearm (5 cm from the wrist) of each participant.
Study NCT05158309 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo patch
Description: A transparent patch with no formulation or effect but the same size of the capsaicin patch was applied to the same location.
Study NCT05117229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MetaWear Sensor
Description: Sensor placed on the pelvis to record spinopelvic movement. Lateral sitting and standing lumbar radiographs will be taken
Study NCT06614309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Placebo Visit
Description: The placebo visit will include 6 simulated cycles of 5 minutes breathing 21% oxygen from a douglas bag and 5 minutes breathing room air.
Study NCT04644289 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: olaparib
Description: Olaparib tablets are administrated orally 300 mg twice daily.